Accueil » Communiqués de presse » Valbiotis announces completion of recruitment for the Phase II/III REVERSE-IT clinical study with TOTUM•63 against prediabetes, in partnership with Nestlé Health Science.
Les communiqués de presse
28Jul2022
Valbiotis announces completion of recruitment for the Phase II/III REVERSE-IT clinical study with TOTUM•63 against prediabetes, in partnership with Nestlé Health Science.
We use cookies to guarantee the best experience on our site, to make statistics, to offer you third party services such as video like Youtube, social networks sharing. By clicking on validate and closing this banner, you accept the deposit of cookies.AcceptRefuseMore information
You can revoke your consent at any time by using the "Revoke Consent" button.Revoke consent
